The Extraneuronal Transport Mechanism for Noradrenaline (uptake2) Avidly Transports 1-methyl-4-phenylpyridinium (MPP+)

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 1992 Aug 1

PMID 1448180

Citations 19

Authors

H Russ

M Gliese

J Sonna

E Schomig

Affiliations

Soon will be listed here.

Abstract

The corticosterone-sensitive extraneuronal transport mechanism for noradrenaline (uptake2) removes the neurotransmitter from the extracellular space. Recently, an experimental model for uptake2 has been introduced which is based on tissue culture techniques (human Caki-1 cells). The present study describes some properties of uptake2 in Caki-1 cells and introduces a new substrate, i.e., 1-methyl-4-phenylpyridinium (MPP+). Experiments on Caki-1 cells disclosed disadvantages of tritiated noradrenaline as substrate for the investigation of uptake2. The initial rate of 3H-noradrenaline transport [kin = 0.58 microliter/(mg protein.min)] was low compared with other cellular transport systems and intracellular noradrenaline was subject to rapid metabolism (kO-methylation = 0.54 min-1). The neurotoxin MPP+ was found to be a good substrate of uptake2. Initial rates of specific 3H-MPP+ transport into Caki-1 cells were saturable, the Km being 24 micromol/l and the Vmax being 420 pmol/(mg protein.min). The rate constant of specific inward transport was 34 times higher [19.6 microliters/(mg protein.min)] than that of 3H-noradrenaline. The ratio specific over non-specific transport was considerably higher for 3H-MPP+ (12.6) than for 3H-noradrenaline (3.0). 3H-MPP+ transport into Caki-1 cells was inhibited by various inhibitors of uptake2. The highly significant positive correlation (p less than 0.001, r = 0.986, n = 7) between the IC50's for the inhibition of the transport of 3H-noradrenaline and 3H-MPP+, respectively, proves the hypothesis that MPP+ enters Caki-1 cells via uptake2. 3H-MPP+ is taken up via uptake2 not only by Caki-1 cells but also by the isolated perfused rat heart which is another established model of uptake2.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Organic cation transporters in psychiatric and substance use disorders.

Honan L, Fraser-Spears R, Daws L Pharmacol Ther. 2023; 253:108574.

PMID: 38072333 PMC: 11052553. DOI: 10.1016/j.pharmthera.2023.108574.

Substrates and Inhibitors of Organic Cation Transporters (OCTs) and Plasma Membrane Monoamine Transporter (PMAT) and Therapeutic Implications.

Bonisch H Handb Exp Pharmacol. 2021; 266:119-167.

PMID: 34495395 DOI: 10.1007/164_2021_516.

Comparative analysis of novel decynium-22 analogs to inhibit transport by the low-affinity, high-capacity monoamine transporters, organic cation transporters 2 and 3, and plasma membrane monoamine transporter.

Fraser-Spears R, Krause-Heuer A, Basiouny M, Mayer F, Manishimwe R, Wyatt N Eur J Pharmacol. 2018; 842:351-364.

PMID: 30473490 PMC: 6440482. DOI: 10.1016/j.ejphar.2018.10.028.

Organic cation transporter 3: A cellular mechanism underlying rapid, non-genomic glucocorticoid regulation of monoaminergic neurotransmission, physiology, and behavior.

Gasser P, Lowry C Horm Behav. 2018; 104:173-182.

PMID: 29738736 PMC: 7137088. DOI: 10.1016/j.yhbeh.2018.05.003.

Characterization of murine polyspecific monoamine transporters.

Miura Y, Yoshikawa T, Naganuma F, Nakamura T, Iida T, Karpati A FEBS Open Bio. 2017; 7(2):237-248.

PMID: 28174689 PMC: 5292661. DOI: 10.1002/2211-5463.12183.

References

Chiba K, Trevor A, Castagnoli Jr N . Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun. 1984; 120(2):574-8. DOI: 10.1016/0006-291x(84)91293-2. View

de la Lande I, Marino V, Lavranos T, Kennedy J, Parker D, Seamark R . Distribution of extraneuronal uptake1 in reproductive tissues: studies on cells in culture. J Neural Transm Suppl. 1991; 34:37-42. DOI: 10.1007/978-3-7091-9175-0_5. View

Van Den Bosch L, De Smedt H, BORGHGRAEF R . Characteristics of Na+-dependent hexose transport in OK, an established renal epithelial cell line. Biochim Biophys Acta. 1989; 979(1):91-8. DOI: 10.1016/0005-2736(89)90527-0. View

Graffe K, STEFANO F, Langer S . Preferential metabolism of (-) 3 H-norepinephrine through the deaminated glycol in the rat vas deferens. Biochem Pharmacol. 1973; 22(10):1147-60. DOI: 10.1016/0006-2952(73)90231-1. View

Schomig E, Korber M, Bonisch H . Kinetic evidence for a common binding site for substrates and inhibitors of the neuronal noradrenaline carrier. Naunyn Schmiedebergs Arch Pharmacol. 1988; 337(6):626-32. DOI: 10.1007/BF00175787. View

Schomig E, Babin-Ebell J, Russ H, Trendelenburg U . The force driving the extraneuronal transport mechanism for catecholamines (uptake2). Naunyn Schmiedebergs Arch Pharmacol. 1992; 345(4):437-43. DOI: 10.1007/BF00176622. View

Grohmann M, Trendelenburg U . The substrate specificity of uptake2 in the rat heart. Naunyn Schmiedebergs Arch Pharmacol. 1984; 328(2):164-73. DOI: 10.1007/BF00512067. View

Iversen L . The uptake of catechol amines at high perfusion concentrations in the rat isolated heart: A novel catechol amine uptake process. Br J Pharmacol Chemother. 2008; 25(1):18-33. PMC: 1510677. DOI: 10.1111/j.1476-5381.1965.tb01753.x. View

Sayre L . Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Lett. 1989; 48(2):121-49. DOI: 10.1016/0378-4274(89)90168-9. View

10.

Javitch J, Snyder S . Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur J Pharmacol. 1984; 106(2):455-6. DOI: 10.1016/0014-2999(84)90740-4. View

11.

Javitch J, DAmato R, Strittmatter S, Snyder S . Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci U S A. 1985; 82(7):2173-7. PMC: 397515. DOI: 10.1073/pnas.82.7.2173. View

12.

Bonisch H, Trendelenburg U . Extraneuronal removal, accumulation and O-methylation of isoprenaline in the perfused heart. Naunyn Schmiedebergs Arch Pharmacol. 1974; 283(2):191-218. DOI: 10.1007/BF00501145. View

13.

Bonisch H, Uhlig W, Trendelenburg U . Analysis of the compartments involved in the extraneuronal storage and metabolism of isoprenaline in the perfused heart. Naunyn Schmiedebergs Arch Pharmacol. 1974; 283(3):223-44. DOI: 10.1007/BF00499185. View

14.

LOWRY O, ROSEBROUGH N, FARR A, RANDALL R . Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1):265-75. View

15.

Schomig E, Schonfeld C . Extraneuronal noradrenaline transport (uptake2) in a human cell line (Caki-1 cells). Naunyn Schmiedebergs Arch Pharmacol. 1990; 341(5):404-10. DOI: 10.1007/BF00176331. View

16.

Fiebig E, Trendelenburg U . The neuronal and extraneuronal uptake and metabolism of 3H-(-)-noradrenaline in the perfused rat heart. Naunyn Schmiedebergs Arch Pharmacol. 1978; 303(1):21-35. DOI: 10.1007/BF00496182. View

17.

Eisenhofer G, Smolich J, Esler M . Disposition of endogenous adrenaline compared to noradrenaline released by cardiac sympathetic nerves in the anaesthetized dog. Naunyn Schmiedebergs Arch Pharmacol. 1992; 345(2):160-71. DOI: 10.1007/BF00165731. View

18.

Nikodejevic B, SENOH S, Daly J, Creveling C . Catechol-O-methyltransferase. II. A new class of inhibitors of catechol-o-methyltransferase; 3,5-dihydroxy-4-methoxybenzoic acid and related compounds. J Pharmacol Exp Ther. 1970; 174(1):83-93. View